相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications
Christian Hampp et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2011)
The relationship between RSV bronchiolitis and recurrent wheeze: The chicken and the egg
L. Bont et al.
EARLY HUMAN DEVELOPMENT (2011)
Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis
Edwin Rietveld et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2010)
Scope and Impact of Early and Late Preterm Infants Admitted to the PICU with Respiratory Illness
Cameron F. Gunville et al.
JOURNAL OF PEDIATRICS (2010)
Risk Factors in Children Hospitalized With RSV Bronchiolitis Versus Non-RSV Bronchiolitis
Carla G. Garcia et al.
PEDIATRICS (2010)
Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life
Nele Sigurs et al.
THORAX (2010)
Cost effectiveness of palivizumab in Spain: an analysis using observational data
Mark J. Nuijten et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2010)
Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention
Dan L. Stewart et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
The Burden of Respiratory Syncytial Virus Infection in Young Children
Caroline Breese Hall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria
Bernhard Resch et al.
CLINICAL THERAPEUTICS (2008)
Consensus paper on prophylaxis against RSV infection with Palivizumab and post-RSV respiratory tract disease
[Anonymous]
MONATSSCHRIFT KINDERHEILKUNDE (2008)
Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants
Bernhard Resch
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children - A UK analysis
Mark J. C. Nuijten et al.
PHARMACOECONOMICS (2007)
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease
Nahed O. ElHassan et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2006)
Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks
B Resch et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2006)
Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13
N Sigurs et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection
A Greenough et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2004)
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
TF Feltes et al.
JOURNAL OF PEDIATRICS (2003)
Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants
JS Sampalis
JOURNAL OF PEDIATRICS (2003)
Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes
SD Horn et al.
JOURNAL OF PEDIATRICS (2003)
Medical progress - Respiratory syncytial virus and parainfluenza virus.
CB Hall
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7
N Sigurs et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
分享论文
